CLINICAL STUDIES

Systematic Lupus Erythematosus (SLE) Study

A Phase 2. randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of M2951 in subjects with systematic lupus erythematosus (SLE)

Study Phase:

Phase 2

Criteria:

  • Male or Female 18 years to 75 years
  • Diagnosed with SLE
Register